MIR Earnings Date: Feb 9, 2027 (Estimated) — Mirion Technologies, Inc.
NYSE · Industrials · Specialty Industrial Machinery
Updated
When is MIR's next earnings date?
Mirion Technologies, Inc. (MIR) is expected to report Q4 2026 earnings on Tuesday, February 9, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.21 on revenue of $339.3M.
How did MIR do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Mirion Technologies, Inc. posted EPS of $0.12 versus the $0.12 estimate, a miss of 0.7%. Revenue was $277.8M against a $275.4M estimate. The stock's 1-day post-earnings move was +8.7%.
How much does MIR stock move after earnings?
MIR beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.4% (up or down) in the day after earnings.
About Mirion Technologies, Inc.
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
🤖 AI Earnings Analysis
Mirion’s industrial monitoring revenue rose 25% year over year to $278M, beating estimates, while EPS was in line at $0.12. Strong 2026 growth guidance of 22–24% supports a constructive outlook.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 0.12 | 0.12 | -0.66% | $277.8M | ❌ Miss | +8.70% | — | — |
| 2026-07-28 | Q2 2026 | 0.10 | 0.12 | +20.00% | $266.8M | ✅ Beat | -13.22% | -3.69% | -11.26% |
| 2026-04-28 | Q1 2026 | 0.09 | 0.10 | +11.11% | $257.6M | ✅ Beat | -0.11% | +7.82% | -8.46% |
| 2026-02-10 | Q4 2025 | 0.16 | 0.15 | -6.25% | $277.4M | ❌ Miss | -10.20% | -8.49% | -14.51% |
| 2025-10-28 | Q3 2025 | 0.10 | 0.12 | +20.00% | $223.1M | ✅ Beat | +18.10% | +10.44% | +2.62% |
| 2025-07-31 | Q2 2025 | 0.10 | 0.11 | +10.00% | $222.9M | ✅ Beat | -11.14% | -3.94% | -8.28% |
| 2025-02-11 | Q4 2024 | 0.15 | 0.17 | +13.33% | $254.3M | ✅ Beat | +1.18% | +4.70% | -12.80% |
| 2024-10-29 | Q3 2024 | 0.09 | 0.08 | -11.11% | $206.8M | ❌ Miss | +4.83% | +6.61% | +15.71% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $277.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 76.9% | $213.5M | +28.5% | $153.2M | $195.8M | $147.9M | $164.2M |
| Service | 23.1% | $64.3M | +12.8% | $53.6M | $58.5M | $54.1M | $58.7M |
By region
Q3 FY26 · $277.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| North America | 71.6% | $198.9M | +37.9% | $138.6M | $155.8M | $130.7M | $138.9M |
| Europe | 27.6% | $76.6M | +1.2% | $65.3M | $95.4M | $65.5M | $81.8M |
| Asia Pacific | 0.8% | $2.3M | -28.1% | $2.9M | $3.1M | $5.8M | $2.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.